A versatile vessel for next-gen therapeutics

Harvard University’s Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules, and other large proteins, to intracellular targets in specific tissues of interest.

Read Press Release

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

Menu